This allowed characterization of non-canonical mutations in BRAF present in adult gliomas; improved estimates of relative frequencies and composition of BRAF alteration types; and integrated clinical-genomic analyses to potentially aid in prognostication. This evidence concerns the gene BRAF and central nervous system cancer.